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Abstract: 
 
 Mounting evidence supports a major role for the Na+/H+ exchanger NHE1 in cancer 
progression and metastasis. NHE1 is hyperactive at the onset of oncogenic transformation, 
resulting in intracellular alkalinization and extracellular microenvironmental acidification. These 
conditions promote invasion and facilitate metastasis. However, the signal pathways governing 
the regulation of exchanger activity are still unclear. This is especially important in the 
aggressively metastatic, triple-negative basal breast cancer subtype. We used affinity 
chromatography followed by mass spectrometry to identify novel and putative interaction 
partners of NHE1 in MDA-MB-231 triple-negative breast cancer cells. NHE1 associated with 
several types of proteins including cytoskeletal proteins and chaperones. We validated protein 
interactions by co-immunoprecipitation for: 14-3-3, AKT, α-enolase, CHP1, HSP70 and HSP90. 
Additionally, we used The Cancer Genome Atlas (TCGA) to study NHE1 gene expression in 
primary patient breast tumours versus adjacent normal tissue. NHE1 expression was elevated in 
breast tumour samples and, when broken down by breast cancer subtype, NHE1 gene expression 
was significantly lower in tumours of the basal subtype compared to luminal and HER2+ 
subtypes. Reverse phase protein array (RPPA) analysis showed that NHE1 expression positively 
correlated with p90RSK expression in basal, but not luminal, primary tumours. Other proteins were 
negatively correlated with NHE1 expression in basal breast cancer tumours. Taken together, our 
data provides the first insight into the signalling molecules that form the NHE1 interactome in 
triple-negative breast cancer cells. These results will focus our search for novel targeted therapies. 
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Highlights: 
 
 Na+/H+ exchanger NHE1 is a signal scaffold in triple-negative basal breast cancer. 
 NHE1 forms a complex with 14-3-3, AKT, α-enolase, CHP1, HSP70 and HSP90. 
 NHE1 positively correlates with p90RSK expression in primary breast tumours. 
 NHE1 associated with cytoskeletal proteins and chaperones 
 NHE1 associated with many proteins that promote breast cancer 
 
 
Abbreviations: 
 
ACC1 (acetyl-CoA carboxylase); AKT (protein kinase B, PKB); CAII (carbonic anhydrase II); 
CHP1 (calcineurin B homologous protein 1); ER (estrogen receptor); ERK1/2 (extracellular 
signal-regulated kinase 1/2); ERM (ezrin-radixin-moesin); FOXO3a (forkhead box O3a); GSK 
(glycogen synthase kinase); HA, hemagglutinin; HER2 (human epidermal growth factor receptor 
2); HSP70/HSP90; heat shock protein70/90; p38MAPK (p38 mitogen-activated protein kinases); 
NF2 (neurofibromin 2);  NHE1, Na+/H+ exchanger isoform 1; PDGF (platelet-derived growth 
factor); PI3K (phosphoinositide-3-kinase); PIP2 (phosphatidylinositol 4,5-biphosphate); PR 
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(progesterone receptor); p90RSK (p90 ribosomal S6 kinase); p160ROCK (rho-associated coiled 
coil-containing protein kinase 1); TNBC (triple-negative breast cancer). 
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1.  Introduction 
 The Na+/H+ exchanger isoform 1 (NHE1 [SLC9A1]) is the major protein involved in the 
regulation of pH homeostasis and is ubiquitously expressed in mammalian cells. Human NHE1 is 
an integral plasma membrane protein comprised of 815 amino acids. The N-terminal 
transmembrane domain consisting of amino acids 1 to 500 is responsible for ion exchange, and 
the C-terminal cytosolic domain of amino acids 501 to 815 regulates the exchanger’s activity via 
phosphorylation or interactions with intracellular signalling molecules [1, 2]. In normal cells, 
NHE1 is activated either by growth factors and hormones in serum, which leads to direct or 
indirect phosphorylation of the exchanger by intracellular signal kinases (e.g. PI3K, ERK1/2, 
p38MAPK), or by binding to a variety of cytosolic proteins and lipids (e.g. ezrin-radixin-moesin, 
14-3-3, calmodulin, phosphatidylinositol 4,5-biphosphate (PIP2), carbonic anhydrase; reviewed in 
[3, 4]). This activation is due to an increased affinity of NHE1’s allosteric proton-binding site for 
intracellular H+ ions [4]. In cancer cells, however, exchanger activity is dysregulated and NHE1 
becomes overactive. The increased activity of NHE1 is pivotal to tumourigenesis. It results in 
increased sodium uptake and elevated proton extrusion that leads to intracellular alkalinization of 
cancer cells and extracellular acidification of the tumour microenvironment [5, 6].  
 In breast cancer, the dysregulation of pH homeostasis and altered dynamics of proton 
transport are critical determinants of metastasis. Elevated intracellular pH with decreased 
extracellular pH is thought to lead to enhanced cellular proliferation and metastasis [6]. Breast 
cancer is a heterogeneous disease with three major molecular profiles: estrogen and/or 
progesterone receptor (ER/PR)-positive; human epidermal growth factor receptor 2 (HER2)-
positive; and triple-negative, which lacks the expression of estrogen, progesterone, or HER2 
receptors [7]. In breast cancer cells, NHE1 becomes hyperactive early in neoplastic 
transformation. This hyper-activation has been shown to be particularly important in triple 
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negative breast cancer [8] where it is primarily responsible for the acidic pH of the tumour 
microenvironment that facilitates metastasis [5]. Inhibiting NHE1 activity, or preventing the 
dysregulation of NHE1, may thus provide an attractive avenue for preventing metastasis of breast 
cancer [3, 8].  This is particularly important for aggressive metastatic triple-negative breast 
cancer for which hormone and HER2-targeted therapies do not work [9].  
 NHE1 regulation is mediated through its cytosolic C-terminal tail by both 
phosphorylation and protein-protein interactions. Phosphorylation of NHE1 directly increases 
exchanger activity in response to hormonal stimulation; however, protein-protein interactions are 
thought to account for approximately 50% of NHE1 activation by growth factors. These protein 
interactions are increasingly considered to be important in NHE1 regulation [3, 10-13]. NHE1 
hyper-activation could be due to an altered regulation of the exchanger’s activity by signal 
kinases and its intracellular binding partners. We recently demonstrated that NHE1 regulation by 
p90RSK via the serine 703 residue can influence the metastatic potential of triple-negative breast 
cancer cells. Additionally, the metastatic potential of breast cancer cells was enhanced by 
mutation of the calmodulin-binding domain to make an artificially hyperactive NHE1 protein 
[14]. 
There has been increasing attention on the role of NHE1 as a signal scaffold in recent 
years.  NHE1 binds signalling complexes including ERK2 in Chinese hamster ovary cells [15, 
16]. It acts as an anchor for actin filaments [13] and binds several regulatory proteins including 
calmodulin [1], HSP70 [17] and others (reviewed in [4]).  As noted above, the enhanced activity 
of NHE1 is critical in metastasis and the protein-mediated regulation of NHE1 is likewise crucial 
in its activity.  However, there is no information available on protein-mediated regulation of 
NHE1 in breast cancer cells, particularly in the triple-negative breast cancer (TNBC) subtype. 
 8 
 In the present study, affinity chromatography followed by mass spectrometry was used to 
identify intracellular protein binding partners of NHE1 in a triple-negative breast cancer model, 
MDA-MB-231 cells. We further validated key intracellular molecular associations that make up 
the NHE1 interactome in these cells by co-immunoprecipitation. Our data was supplemented by 
an analysis of The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/) database, 
where we compared NHE1 gene expression in primary patient breast tumours and normal breast 
tissue. Reverse phase protein array (RPPA) clinical data from TCGA was used to examine 
correlations in NHE1 mRNA expression with that of signal proteins of primary breast tumours by 
subtype versus normal tissue. We also looked for correlations between NHE1 expression and 
other interacting proteins or signal kinases. Our data, for the first time, provide insight into the 
NHE1 signal scaffold that regulates metastasis in triple-negative basal-like breast cancer and 
could provide critical insights for the development of novel chemotherapeutics targeted towards 
TNBC. 
 
2.  Materials and Methods 
 
2.1.  Cell lines and culture conditions 
  
 MDA-MB-231 breast cancer cells were cultured in high-glucose modified DMEM 
(HyClone) supplemented with 10% fetal calf serum (HyClone), 10 mM HEPES, and 1000 
units/ml penicillin/streptomycin (Gibco) under standard culture conditions (5% CO2, 37°C and 
high humidity). Low serum media, to activate NHE1, contained 0.2% serum but was otherwise 
identical in composition. We used a previously generated stable MDA-MB-231 cell line where 
the endogenous NHE1 was knocked out [8] and replaced with a hemagglutinin (HA) tagged 
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NHE1 protein that does not interfere with NHE1 activity [18]. Cells expressing wild-type HA-
tagged NHE1 protein were grown in the presence of 400 g/ml G418 (Geneticin Sulfate, Santa 
Cruz). DNA analysis (DDC Medical, Ohio) was used to authenticate parental MDA-MB-231 
cells, which showed >95% homology to the ATCC STR profile. 
 
2.2.  Preparation of Cell Lysates 
  
 Seventy-five 150 mm plates of MDA-MB-231 cells were grown in standard medium and 
lysis buffer [20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1% Triton X-100, and 
protease inhibitors] was added to generate whole cell lysates. Lysates were centrifuged at 10,000 
rpm for 15 min. at 4°C and the supernatant was used for affinity chromatography. 
 
2.3.  Protein Expression and Purification 
  
 Affinity chromatography was used to identify the interacting protein partners of NHE1 in 
MDA-MB-231 breast cancer cell lysates as previously described [19]. The C terminus of the 
rabbit NHE1 spanning amino acids 545 to 816 was produced as a glutathione S-transferase (GST) 
fusion protein [17]. The primer pair used for amplification of the sequence was 5'-
acggatccattggaaagacaagctcaaccggttta-3' and 5'-aagaattcactgccctttggggatgaaaggct-3'. For cloning 
and expression, the pGEX-3X plasmid in the BamHI-EcoRI sites was utilized. GST was 
produced using the same plasmid without an exogenous insert (control). Proteins were expressed 
in TOP2 Escherichia coli and a single colony was selected for overnight culture. After induction 
for 5 hours at 30°C with isopropyl -D-thiogalactopyranoside, bacterial cultures were centrifuged 
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in lysis buffer at 7,000 rpm at 4°C prior to sonication of the pellet to induce greater cell 
disruption and protein extraction. Debris was removed by further centrifugation at 20,000 rpm at 
4°C and the supernatant collected and filtered before transferring to column. Purification from the 
supernatant was essentially as described earlier [19] using a glutathionine-agarose column. The 
supernatant was loaded onto the column and passed through it twice. The column was washed 
with 20 volumes of phosphate buffered saline and eluates with the purified protein were collected 
and centrifuged at 3,000  g. Purified proteins were resuspended in 0.1 M MOPS buffer with 80 
mM CaCl2 (pH 7.5) and concentrated. Five mg of either GST or NHE1-GST proteins were bound 
to Affi-Gel 10 beads (Bio-Rad) as described by the manufacturer. After blockage of any 
remaining reactive esters and washing, MDA-MB-231 cell lysates were then passed through the 
Affi-Gel 10 column 10 times and the column was washed. Bound proteins were eluted with 
buffer [20 mM HEPES, pH 7.2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1% SDS 
and protease inhibitors], and precipitated with trichloroacetic acid. Precipitates were separated by 
SDS-PAGE and separated proteins were cut from the gel for further analysis by mass 
spectrometry. 
 
2.4.  Sample Preparation and Mass Spectrometry 
  
 The samples were digested with trypsin in-gel.  Briefly, the excised gel bands were de-
stained twice in 100 mM ammonium bicarbonate/acetonitrile (50:50). The samples were then 
reduced with 10 mM BME in 100 mM bicarbonate and the alkylated with 55 mM iodoacetamide 
in 100 mm bicarbonate. After dehydration, gel segments were digested with trypsin (6 ng/μL) 
overnight at room temperature. Tryptic peptides were extracted from the gel with a 97% 
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water/2% acetonitrile/1% formic acid solution, followed by a second extraction using 50% of the 
first extraction buffer and 50% acetonitrile.  
 Fractions containing tryptic peptides dissolved in aqueous 25% v/v acetonitrile and 1% 
v/v formic acid were resolved and ionized by using nanoflow HPLC (Easy-nLC II, Thermo 
Scientific) coupled to the LTQ XL-Orbitrap hybrid mass spectrometer (Thermo Scientific). 
Nanoflow chromatography and electrospray ionization were accomplished by using a PicoFrit 
fused silica capillary column (ProteoPepII, C18) with 100 μm inner diameter (300Å, 5μm, New 
Objective). Peptide mixtures were next injected onto the column with a flow rate of 3,000 nL/min 
and were resolved at 500 nL/min using 70 min linear gradients from 0 to 45% v/v aqueous ACN 
in 0.2% v/v formic acid. The mass spectrometer was operated in a data-dependent acquisition 
mode, recording high-accuracy and high-resolution survey Orbitrap spectra using external mass 
calibration, with a resolution of 60,000 and m/z range of 400 to 2,000. The fourteen most intense 
multiply charged ions were sequentially fragmented using collision-induced dissociation, and the 
spectra of their fragments were recorded in the linear ion trap. After two fragmentations, all 
precursors selected for dissociation were dynamically excluded for 60 sec.   
 Data were processed using Proteome Discoverer 1.4 (Thermo Scientific) and SEQUEST 
was used to search the Uniprot Human protein database (Thermo Scientific).  Search parameters 
included a fragment mass tolerance of 0.8 Da and a precursor mass tolerance of 10 ppm. Peptides 
were searched with the dynamic modifications of carbamidomethyl cysteine as a static 
modification and oxidized methionine and deamidated glutamine and asparagine. Data shown are 
representative of three independent experiments. 
 
2.5.  Co-immunoprecipitation and Immunoblotting 
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Cells were stimulated (+, 0.2% serum) or not (−,10% serum) overnight prior to adding 2.5 
mM DSP (dithiobis[succinimidyl propionate]), an amine-reactive cleavable cross-linker (Thermo 
Scientific). Incubation with DSP was for 2 hours on ice in the dark. The reaction was stopped 
with 30 mM Tris (Fisher BioReagents) for 15 min. prior to lysis with RIPA buffer (50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 80 mM NaF, 5 mM EDTA, 1 mM EGTA, 1 mM Na-orthovanadate, 
1 % NP-40, 0.05 % deoxycholate and protease inhibitor cocktail). After centrifugation, 25 μL of 
pre-washed HA-tagged beads (Santa Cruz Biotechnology) was added to the supernatant and 
incubated overnight at 4°C. Beads were removed by centrifugation and washed with phosphate 
buffered saline (PBS, 150 mM NaCl, 5 mM sodium phosphate, pH 7.4). Samples were boiled in 
SDS before separation on SDS-PAGE gels.  Western blotting was onto nitrocellulose membranes. 
Co-immunoprecipitation of putative protein interaction partners of NHE1 was confirmed by 
immunoblot analysis. Blots were incubated overnight with the following antibodies against 
targeted proteins: AKT (Cell Signalling Technologies); α-Enolase (ProteinTech); HA-probe, 
CHP1 and 14-3-3 (Santa Cruz Biotechnologies); and HSP70 and HSP90 (Enzo Life Sciences). 
Chemiluminescence was used to detect immunoreactive co-precipitating proteins. 
 
2.6.  Bioinformatics 
  
 An analysis of primary patient clinical samples in The Cancer Genome Atlas (TCGA; 
https://tcga-data.nci.nih.gov/tcga/) database was used to evaluate NHE1 gene expression in 
normal breast tissue versus primary breast tumours. Level 3 TCGA RNAseqV2 gene expression, 
reverse phase protein array (RPPA), and clinical data from 1062 breast cancer and 113 associated 
normal patient samples were obtained from the TCGA Data Portal (https://tcga-
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data.nci.nih.gov/tcga/) in August 2014. Subtype data for tumours was accessed from the UCSC 
cancer genome browser (RNASeqV2 defined). All statistical analyses and visualizations for 
bioinformatics datasets were conducted in the RStudio programming environment (v0.98.501). 
R/Bioconductor packages ggplot2 and plyr were used where appropriate.  
 
3.  Results 
  
3.1.  Determination of NHE1 interacting partners by mass spectrometry  
  
 We used mass spectrometry analysis in order to determine potential novel intracellular 
interaction partners of NHE1 in triple-negative MDA-MB-231 breast cancer cells (Table 1). An 
affinity chromatography-based protein purification method using a glutathione S-transferase 
(GST) fusion protein of the C terminus of the rabbit NHE1 spanning amino acids 545 to 816 
(NHE1-GST) was used to detect protein-protein interactions in MDA-MB-231 cell lysates. 
Interacting proteins unique to the NHE1-GST sample were selected based on the number of 
detected peptide spectral matches (PSM). The highest number of PSMs was attributed to NHE1 
(SLC9A1), indicating the presence of NHE1 homodimers, which has been reported earlier [20]. 
Several proteins involved in cellular biosynthesis, metabolism, signal transduction, and 
cytoskeletal organization were found to uniquely interact with NHE1 (over the control) as listed 
in Table 1. For interacting proteins present in both the GST control and the NHE1-GST sample, 
the binary logarithm of the ratio of the number of PSMs in the sample versus control was 
calculated (log2[PSMNHE1-GST/PSMGST]). A two-fold or higher detection of interacting proteins in 
the sample over the control was considered significant (Table 2).  
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3.2.  Validation of NHE1 interaction partners by co-immunoprecipitation 
 
 We validated several putative intracellular protein binding partners of NHE1, both as 
determined by the above MS analysis and previous studies (reviewed in [3]), by co-
immunoprecipitation of HA-tagged NHE1 with target proteins. In breast cancer cells, NHE1 
becomes hyper-active (stimulated) with serum deprivation [14, 21, 22]. We cultured MDA-MB-
231 cells in stimulated (+, serum-deprived, 0.2% serum) and unstimulated (−, serum-
supplemented, 10% serum) conditions prior to lysis and co-immunoprecipitation. This was 
followed by immunoblotting with antibodies against target proteins. NHE1 was found to co-
immunoprecipitate with: AKT (protein kinase B, PKB), α-enolase, CHP1 (calcineurin 
homologous protein 1), 14-3-3, and heat shock proteins HSP70 and HSP90 [Fig. 1; N=3]. No 
significant differences in the interaction of NHE1 with AKT, CHP1, HSP70 or HSP90 were 
observed between stimulated and unstimulated cells. However, in stimulated MDA-MB-231 cells 
where basal NHE1 exchange activity is significantly higher [14, 21], the dimeric form of 14-3-3 
was associated with NHE1 in greater amounts than the monomeric form. Also, α-enolase is 
mainly associated with NHE1 in stimulated cells.  
 
3.3.  Na+/H+ exchanger NHE1 mRNA expression in primary patient clinical breast cancer 
 subtypes 
  
 The Cancer Genome Atlas (TCGA; www.cancergenome.nih.gov), an initiative of the 
National Cancer Institute and the National Human Genome Research Institute, is a cancer 
genomic database containing tumour tissue and normal tissue samples from hundreds of patients. 
We used TCGA to analyze the expression of NHE1 mRNA in primary breast tumours and 
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associated normal mammary tissue from patient samples (n=1062 and 113, respectively). Our 
analysis revealed that NHE1 mRNA expression significantly increased in breast tumour samples 
over their matched normal counterparts (Fig. 2a, *P<0.001). When expression levels were 
examined by breast cancer subtype, however, we found significantly decreased NHE1 expression 
in the basal subtype compared to luminal and HER2+ subtypes [23] (Fig. 2b, *P<0.001).  Though 
NHE1 expression levels tended to be higher than normal in HER+ tumours, this effect was not 
significant.  
 
3.4.  Reverse phase protein array (RPPA) analysis of NHE1 interacting partners from 
 primary patient tumours 
 
 Reverse phase protein arrays (RPPA) are a high-throughput, antibody-based 
determination of protein expression levels in primary patient tumour tissue samples from TCGA. 
We analyzed correlations of NHE1 mRNA expression with that of proteins in primary tumours 
from patients with the basal (triple-negative) clinical subtype of breast cancer using the RPPA-
TCGA database (N=220). As seen in Table 3, NHE1 expression levels positively and 
significantly correlated with the expression of: phospho-p90RSK (pT359/pS363; r = 0.31), 
phospho-GSK3 (α(pS21), β(pS9); r = 0.31), β-catenin (r = 0.27), AKT (pS473; r = 0.26), NF2 
(neurofibromin 2; r = 0.24), and Src (pY416; r = 0.23). A further analysis of NHE1 mRNA 
expression levels in basal versus luminal breast cancer samples revealed a weakly positive but 
significant correlation of NHE1 with phospho-p90RSK (T359/S363) protein expression in only 
basal-type cancers (r = −0.05 in luminal samples versus r = 0.31 in basal samples; Fig. 3). 
Additionally, NHE1 expression in basal breast cancer tumours negatively correlated with the 
expression of: Notch1 (r = −0.22), FOXO3a (forkhead box O3a; r = −0.23), ACC1 (acetyl-CoA 
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carboxylase; r = −0.23), p27 (pT157; r = −0.24), Chk1 (r = −0.25), Smad4 (r = −0.25), and cyclin 
B1 (r = −0.26) (Table 3). 
 
4.  Discussion 
  
NHE1 is regulated by both kinase-mediated phosphorylation and by interactions with 
intracellular proteins and lipids that modulate its activity. These regulators primarily affect NHE1 
activity by shifting its pH versus activity curve to make it more active at more alkaline 
intracellular pH [3, 11-13]. In transformed cells, cytoplasmic alkalinization brought about by 
increased Na+ uptake is largely driven by NHE1 and is a critical step in tumourigenesis. The 
resultant increased H+ efflux also mediates metastasis by providing a more acidic extracellular 
microenvironment that not only promotes the development of a more invasive cell phenotype [6], 
but is also optimal for the activity of secreted serine proteases and matrix metalloproteinases.  
These proteolytic enzymes digest a path through the extracellular matrix allowing for cells to 
leave the primary tumour and enter the bloodstream [24, 25]. It is also of note that elevated 
NHE1 activity contributes of sodium loading of cells.  Elevated sodium loading by NHE1 and 
other sodium loading proteins such as sodium channels and Na+/HCO3
- co-transport, may 
promote mitogenesis and/or oncognesis [26-30] and elevated tissue sodium is reported in 
malignant breast cancer [31] and other cancer types [32, 33]. Thus elevated NHE1 activity may 
contribute to oncogenesis by more than one mechanism.  
Since the elevated activity of NHE1 contributes to metastasis, there is great interest in 
deciphering how this activity is regulated in breast cancer cells. In other tissues, the cytosolic C-
terminal tail of NHE1 is a binding site for signal kinases, regulatory proteins, and linkages to the 
cell cytoskeleton [4, 13, 15, 16] suggesting that it is acting as a scaffolding rather than an adaptor 
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protein. In this study, we used different approaches to identify individual molecular players 
associated with the NHE1 signal scaffold in breast cancer. We looked at direct interactions 
determined by affinity chromatography and identified by mass spectrometry and we also 
analyzed hundreds of primary patient tumour samples characterized by The Cancer Genome 
Atlas.  
 
4.1.  NHE1 and cytoskeletal proteins 
 
Our affinity chromatography experiments identified alpha-actinin-4, moesin, ezrin, F-
actin-capping protein, talin-1, profilin and alpha-actinin-1 (Table 1, 2) as cytoskeletal proteins 
from MDA-MB-231 cells that were associated with the cytosolic tail of NHE1. Our study is the 
first identification of the association of most of these proteins with NHE1 in this cell type, which 
is representative of basal triple-negative breast cancer.  However, many of these and related 
proteins have been suggested to be involved with NHE1 in other cell types.  Ezrin and moesin 
(and radxin) are known to bind to NHE1 [34]; in fact, ezrin co-localizes with NHE1 in MDA-
MB-231 cells [35]. We also found talin-1 associated with NHE1. Talin is a large protein that 
links integrins to the actin cytoskeleton, binds moesin, and recruits a moesin-NHE1 complex to 
invadopodia, stabilizing them and promoting matrix degradation [36].  
Our results also revealed novel interactions of NHE1 with the actin-binding proteins 
alpha-actinin 1 and 4, and profilin-1 in MDA-MB-231 cells. Alpha-actinin-1 and 4 are the non-
muscle isoforms of the protein generally believed to be structural components of F-actin cohesion 
in cells [37]. Alpha-actinin-4 is upregulated in some types of cancer and promotes proliferation of 
luminal MCF-7 breast cancer cells [37, 38]. Profilin is a ubiquitously expressed actin-binding 
protein that can regulate invadopodia maturation [39] and is overexpressed in breast cancer cells 
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[40]. To our knowledge, profilin-1 has not been previously shown to be associated with NHE1, 
and this interaction is intriguing considering its role in invadopodia maturation [39]. However, 
we were unable to confirm these interactions further by co-immunoprecipitation. 
 
4.2.  NHE1 and chaperone proteins 
 
Various chaperone proteins were also identified as associating with NHE1 by affinity 
chromatography, including heat shock proteins. We confirmed the interaction of HSP70 and 
HSP90 with NHE1 by co-immunoprecipitation.  NHE1 and HSP70 were previously shown to 
interact in PS127A Chinese hamster fibroblasts [17].  More recently [41], HSP70 was found to be 
dynamically associated with NHE1 in macrophages.  Heat shock proteins are inducible molecular 
chaperones that facilitate the folding of proteins and their transport across membranes, and 
prevent protein aggregation in response to cellular stress. Tumour cells express higher levels of 
HSP70 and HSP90, which play a role in metastasis, proliferation and protection against apoptosis 
[42]. This leaves open the possibility that some of their actions are mediated through NHE1, 
which also facilitates tumour cell metastasis [8, 14].  
Other chaperones found associated with NHE1 included protein disulfide isomerase, 
peroxiredoxin-2, thioredoxin, calnexin and calreticulin. These proteins are likely involved in the 
folding of NHE1. Several laboratories [43, 44] have shown that elevated NHE1 expression is 
associated with increased calreticulin and protein disulfide isomerase expression, implicating an 
association of some of these proteins with NHE1 in other tissues.  Glucose-regulated proteins 
were also increased with elevated NHE1 expression in the myocardium [43]. Here, we found an 
association of 78 kDa glucose-regulated protein with NHE1 (Table 2). Endoplasmin, which was 
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also found associated with the NHE1 tail (Table 1), is known to be elevated in breast cancer with 
distant metastasis and is associated with decreased patient survival [45].  
 
4.3.  NHE1 and biosynthetic proteins 
 
We identified several proteins of biosynthetic pathways associated with NHE1 including 
glutamate dehydrogenase, fructose-bisphosphate aldolase, transketolase, glyceraldehyde-3-
phosphate dehydrogenase and α-enolase (Table 1, 2). α-enolase is a cytosolic glycolytic enzyme 
and oxidative stress protein. Its expression is elevated in many tumours, including those of the 
breast, where it is also found on the cell surface [46, 47]. The NHE1-α-enolase complex was 
confirmed by both affinity chromatography and co-immunoprecipitation. Interestingly, α-enolase 
was found to be more strongly associated with NHE1 from cells cultured in stimulated, serum-
depleted conditions where the exchanger is hyperactive. The physiological significance of such 
associations are not clear; however, glycolytic enzymes are known to bind to other membrane 
proteins, such as band 3, and the binding process assists in regulation of metabolism [48]. 
Whether NHE1 plays a similar role is not known. The only kinase found to be directly associated 
with the NHE1 cytosolic tail in affinity chromatography experiments was phosphoglycerate 
kinase, which plays a role in regulating the glycolytic pathway.  
 
4.4.  NHE1 and signal transduction proteins 
 
Calcineurin homologous protein 1 (CHP1) has been shown to form a complex with the 
cytosolic domain of NHE1, helping to stabilize it at the cell surface in some cell types [4, 49]. 
Surprisingly, we did not find CHP1 associated with NHE1 by affinity chromatography 
 20 
experiments but were able to demonstrate an association with NHE1 through co-
immunoprecipitation from MDA-MB-231 cells. Other proteins found associated with NHE1 by 
affinity chromatography experiments included: cathepsin D, galectin 1, voltage-dependent anion 
selective channel protein 1, a chloride channel, a 40s ribosomal protein SA, nucleolin and 
heterogeneous nuclear ribonucleoprotein A1. Some of these proteins have an association with 
cancer progression. For example, cathepsin D is a lysosomal protease overexpressed in many 
metastatic breast cancer cell lines and its presence in the cytosol of primary breast tumours is 
indicative of an increased risk of metastatic disease [50]. Galectin-1 is a β-galactosidase-binding 
protein thought to be involved in cell-cell interactions. It is abnormally expressed in cancer cells 
and increased expression in many cancers, including breast cancer, is generally associated with 
poor prognosis [51]. Nucleolin is also overexpressed in breast cancer cell populations [52]. Our 
attempts to validate the interaction of cathepsin D with NHE1 by co-IP experiments were 
unsuccessful; validation of the other protein-protein interactions were not attempted at this time. 
Significantly, we identified several isoforms of 14-3-3 proteins that bind to the NHE1 tail 
region by affinity chromatography (Table 1, 2) and this was confirmed by co-
immunoprecipitation experiments. 14-3-3 proteins bind intracellular ligands which include signal 
kinases, phosphatases and other proteins. The 14-3-3 proteins have been demonstrated to interact 
with the NHE1 tail.  They regulate phosphorylation of serine 703 of NHE1 in the muscle tissues 
[53, 54]. 14-3-3 binding to NHE1 in breast cancer cells has not been reported. We have, however, 
previously demonstrated that serine 703, the binding site of 14-3-3 on the NHE1 C-terminal, 
plays an important role in the regulation of epithelial-mesenchymal transition of triple-negative 
MDA-MB-231 breast cancer cells [14]. These results support the suggestion that 14-3-3 binding 
to NHE1 is important in the regulation of the exchanger in TNBC cells. Furthermore, this data 
also supports the idea that NHE1 is acting more as a scaffold protein, as opposed to just an 
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adaptor protein, with definitive functional consequences to many of these interactions as 
suggested earlier [15].  
 
4.5.  NHE1 expression and protein associations in primary patient breast tumours 
 
To supplement the above findings, we examined correlations in the expression of NHE1 
and other signal proteins in primary patient tumours. We previously used the ONCOMINETM 
database [21] to show that, in a comparison of multiple cancers versus matched normal tissue, 
NHE1 mRNA expression is elevated in some types of cancer including breast cancer. In this 
study, we used The Cancer Genome Atlas (TCGA) to analyse NHE1 mRNA expression in 
primary patient breast tumours of various clinical subtypes. The TCGA is a more robust RNA-
sequencing database with a much larger patient breast tumour and normal tissue cohort. The 
TCGA also has an additional analytic capability linked to a reverse phase protein array (RPPA) 
database that enables the comparison of the expression of multiple proteins with a particular gene 
of interest. A limitation is that NHE1 expression can only be determined at the mRNA level in 
currently available tumour genomics databases. Despite this limitation, useful information can 
still be collected from this analysis that will lead to further investigations.   
Our initial TCGA analysis showed that NHE1 mRNA expression was significantly higher 
in breast tumours than in normal mammary tissue (Fig. 2a). Interestingly, a more in-depth 
analysis classified by specific breast cancer subtypes (luminal A and B, HER2-amplified and 
basal) revealed that NHE1 mRNA expression is mostly unchanged in luminal and HER2-
amplified tumours and actually lower in basal (triple-negative) tumours compared to normal 
mammary tissue (Fig. 2b). The reason for this discrepancy is unclear. However, it is possible that, 
based on the sample sizes for the two analyses (see legends for Fig. 2a and 2b), the subtype-
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specific tumour tissues in Fig. 2b may only account for a percentage of the sample pool used to 
generate Fig. 2a.  
The lower NHE1 mRNA expression in basal breast tumours may be indicative of a 
likewise lower expression of NHE1 protein. At first glance, this result appears to contradict the 
suggestion that NHE1 plays an important role in breast tumour progression. Particularly since the 
basal subtype represents the most aggressively metastatic cancers. However, NHE1 is a tightly 
regulated protein that is modulated by both phosphorylation and protein binding, and the 
regulation of its activity is critical in metastatic basal-like breast cancer cells. More NHE1 protein, 
if inactive, would not affect intracellular pH. Several laboratories, including ours, have shown 
that NHE1 is hyper-activated in breast cancer cells in the acidic, hypoxic, and serum-depleted 
tumour microenvironment [5, 8, 14]; in our studies, this increased activity was not accompanied 
by a similar increase in NHE1 protein expression. In heart disease an analogous situation exists. 
The activation of NHE1, and not increased expression of the protein per se, is the critical factor 
determining NHE1-mediated disease progression [55]. Further to this end, we recently 
demonstrated that replacement of endogenous NHE1 in MDA-MB-231 cells with a hyperactive 
NHE1 protein resulted in an increased metastatic behaviour of this cell line [14]. This also 
supports the hypothesis that activation and regulation of NHE1 are critical determinants.   
We used the TCGA-RPPA database to identify correlations between NHE1 mRNA 
expression and a number of intracellular signalling molecules. We found several novel, as well as 
previously identified, potential regulators of the protein. p90RSK and AKT (protein kinase B) are 
known to regulate NHE1 activity. p90RSK phosphorylates NHE1 at Ser703 and stimulates its 
activity, mediating growth factor activation of the protein in some cell types [4, 56]. We recently 
showed that a mutation at serine 703 to non-phosphorylatable alanine markedly changed the 
morphology of MDA-MB-231 breast cancer cells from a mesenchymal to a more epithelial-like 
 23 
phenotype with a concomitant loss of metastatic potential [14]. In this study, we found a weak 
but significant positive correlation between NHE1 mRNA and the expression of phosphorylated 
p90RSK at the protein level in primary metastatic basal (triple-negative), but not luminal, breast 
tumours (Fig. 3). This leaves open the possibility that p90RSK-mediated phosphorylation of NHE1 
is at least partially responsible for the aggressive metastatic behaviour of TNBC cells. Indeed, we 
have previously demonstrated that BI-D1870, a specific inhibitor of p90RSK, inhibits the 
metastatic potential of several TNBC cell types, supporting this hypothesis [14]. Though these 
results are significant, the pattern of the positive correlation is dispersed. The reason for this is 
not immediately clear but could be due to the influence of other NHE1 regulators.  
Another kinase known to regulate NHE1 is AKT. The exact role of AKT-mediated 
phosphorylation of NHE1 is dependent on cell type [4]. In the myocardium, NHE1 activity is 
inhibited by AKT-mediated phosphorylation of serine 648 [57, 58]. However, in fibroblasts, 
AKT phosphorylation of NHE1 is stimulatory, induces cytoskeletal remodeling, and is necessary 
for the activation of NHE1 by insulin and PDGF [59]. We confirmed that AKT interacts with 
NHE1 in MDA-MB-231 cells by co-immunoprecipitation experiments (Fig. 1). TCGA-RPPA 
analysis showed that AKT protein expression in patient tumours of the triple-negative basal 
clinical subtype positively, correlated with NHE1 expression though weakly (Table 3).  
Other proteins that were found to weakly, positively correlate with NHE1 in RPPA were 
pGSK3, NF2, Src and -catenin. To our knowledge, the direct demonstration of these 
correlations with NHE1 in triple-negative breast cancer would be novel and could be the subject 
of future investigations. Potential phosphorylation sites for GSK3 exist [4]. The expression of 
some proteins negatively correlated with NHE1 mRNA expression (Table 3). The significance of 
this is not yet clear.  
 24 
 
Conclusion 
 In breast cancer, the dysregulation of pH homeostasis chiefly caused by hyper-activation 
of NHE1 plays a critical role in triggering and sustaining metastasis, where altered dynamics of 
Na+/H+ exchange are a key determinant of metastatic potential. This hyper-activation of NHE1 is 
particularly important in triple-negative breast cancer where it is primarily responsible for the 
acidic pH of the tumour microenvironment that facilitates metastasis [5, 6, 8]. NHE1 is regulated 
by protein-protein interactions and by phosphorylation/dephosphorylation. Here, we examined 
proteins binding to NHE1 in triple-negative breast cancer cells and those correlating with NHE1 
gene expression in primary patient breast tumour samples. We found many categories of proteins 
binding to the NHE1 regulatory cytosolic domain including several cytoskeletal, chaperone, 
biosynthesis, and signalling proteins. It is noteworthy that many NHE1-binding proteins have 
elevated expression in breast and other cancer types; this raises the possibility that their function 
could impact NHE1 activity (or vice versa) and contribute to its role in metastasis. Our study is 
the first definition of the interactome of NHE1 in triple-negative breast cancer cells. 
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Figure Legends: 
 
Figure 1: Validation of MS-determined protein interaction partners of NHE1 by co-
immunoprecipitation. Potential protein interaction partners of NHE1 as determined by affinity 
chromatography, were evaluated by co-immunoprecipitation with HA-tagged NHE1 in 
stimulated (+, 0.2% serum) and unstimulated (−, 10% serum) culture conditions as described in 
the “Materials and Methods”. Validated interaction partners of NHE1 were: 14-3-3, AKT 
(protein kinase B, PKB), CHP1 (calcineurin B homologous protein 1), α-Enolase, and heat shock 
proteins HSP70 and HSP90 [N=3]. 
 
Figure 2: The Cancer Genome Atlas (TCGA) analysis of NHE1 mRNA expression in 
primary patient breast cancer tumours versus normal breast tissue. a, NHE1 mRNA 
expression is higher in breast cancer tumours versus associated tissue controls. Comparison of the 
mean expression values (RSEM normalized values) of breast cancer tumours (N=1062) and 
associated normal tissue (N=113). Bars represent means +/− SEM. Significance was determined 
by Student’s t-test [*P<0.001]. b, NHE1 mRNA expression values in breast cancer tumours by 
subtype. Comparison of the mean expression values (RSEM normalized values) of Normal 
(N=23), Luminal A (N=421), Luminal B (N=192), HER2 enriched (N=67), and basal (N=141) 
breast cancer subtypes.  Significance was determined by a one-way ANOVA followed by 
Tukey’s HSD [*P<0.001]. 
 
Figure 3. NHE1 expression correlates with phospho-p90RSK levels in basal, but not luminal, 
primary breast cancer samples. Phospho-p90RSK (T359/S363) values (RPPA values) were 
analyzed for correlation with NHE1 expression values (RSEM normalized counts) in (a) luminal 
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breast cancer samples (n=141) and (b) basal breast cancer samples (n=79). The grey line is the 
regression line and grey shading depicts the 95% confidence interval of the fit. Spearman 
correlation coefficients (r) with calculated P values are indicated.  
  
 35 
Tables: 
 Table 1: List of NHE1-interacting peptides unique to NHE1-GST versus GST-control analysis. 
 
 
Accession # 
 
Protein [GENE] 
 
PSM 
 
Function: 
 
P19634 Sodium/hydrogen exchanger 1 [SLC9A1] 57 Homodimer  
P10809 60 kDa heat shock protein, mitochondrial [HSPD1] 42 Biosynthesis  
P29401 Transketolase [TKT] 35 Biosynthesis 
O43707 Alpha-actinin-4 [ACTN4] 31 Cytoskeletal activity 
P07900 Heat shock protein HSP 90-alpha [HS90AA1] 32 Signal transduction 
P08107 Heat shock 70 kDa protein 1A/1B [HSPA1] 29 Signal transduction 
P00558 Phosphoglycerate kinase 1 [PGK1] 24 Metabolism 
P08865 40S ribosomal protein SA [RPSA] 19 Biosynthesis 
P19338 Nucleolin [NCL] 20 Biosynthesis 
P09651 Heterogeneous nuclear ribonucleoprotein A1 [HNRNPA1] 18 Biosynthesis 
P00367 Glutamate dehydrogenase 1, mitochondrial [GLUD1] 19 Biosynthesis 
P09382 Galectin-1 [LGALS1] 14 Signal transduction 
P04075 Fructose-bisphosphate aldolase A [ALDOA] 17 Metabolism 
P0CG48 Polyubiquitin-C [UBC] 15 Biosynthesis 
P07339 Cathepsin D [CTSD] 14 Signal transduction 
P26038 Moesin [MSN] 13 Cytoskeletal activity 
P14625 Endoplasmin [HSP90B1] 12 Biosynthesis 
P32119 Peroxiredoxin-2 [PRDX2] 12 Metabolism 
P07237 Protein disulfide-isomerase [P4HB] 10 Biosynthesis 
P08758 Annexin A5 [ANXA5] 10 Signal transduction 
P62258 14-3-3 protein epsilon [YWHAE] 9 Signal transduction 
O00299 Chloride intracellular channel protein 1 [CLIC1] 8 Metabolism 
P21796 Voltage-dependent anion-selective channel protein 1 [VDAC1] 8 Biosynthesis 
P27824 Calnexin [CANX] 7 Biosynthesis 
O00303 Eukaryotic translation initiation factor 3 subunit F [EIF3F] 7 Biosynthesis 
P27348 14-3-3 protein theta [YWHAQ] 6 Signal transduction 
P15311 Ezrin [EZR] 6 Cytoskeletal activity 
P27797 Calreticulin [CALR] 6 Biosynthesis 
P31947 14-3-3 protein sigma [SFN] 4 Signal transduction 
P52907 F-actin-capping protein subunit alpha-1 [CAPZA1] 4 Cytoskeletal activity 
P52565 Rho GDP-dissociation inhibitor 1 [ARHGDIA] 4 Biosynthesis 
Q9Y490 Talin-1 [TLN1] 3 Cytoskeletal activity 
A8MWD9 Putative small nuclear ribonucleoprotein G-like protein 15 [SNRPGP15] 2 Biosynthesis 
P10599 Thioredoxin [TXN] 2 Metabolism 
P45880 Voltage-dependent anion-selective channel protein 2 [VDAC2] 2 Biosynthesis 
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 Table 2: List of NHE1-interacting peptides showing a two-fold increase or greater expression in 
 NHE1-GST analysis versus GST-control. 
 
 
Accession # 
 
Protein [GENE] 
 
log2[PSMNHE1-GST/PSMGST] 
 
Function: 
 
P06733 Alpha-enolase [ENO1] 4.7 Metabolism 
P63104 14-3-3 protein zeta/delta [YWHAZ] 3.5 Signal transduction 
P11021 78 kDa glucose-regulated protein [HSPA5] 3.1 Biosynthesis  
P07737 Profilin-1 [PFN1] 3.0 Cytoskeletal activity 
P08238 Heat shock protein HSP 90-beta [HS90AB1] 2.5 Signal transduction 
P12814 Alpha-actinin-1 [ACTN1] 2.4 Cytoskeletal activity 
P32969 60S ribosomal protein L9 [RPL9] 2.1 Biosynthesis  
P04406 Glyceraldehyde-3-phosphate dehydrogenase [GAPDH] 2.0 Metabolism 
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Table 3: List of NHE1 reverse phase protein array (RPPA) correlations in primary tumour 
samples from patients with the basal clinical subtype of breast cancer (N=79). Significant 
Spearman correlation coefficient (r, positive and negative) values are presented with 
corresponding P values > 0.05. 
 
 
Antibody 
 
Function 
 
r 
 
P Value 
 
p90RSK 
(pT359/pS363) 
Serine/threonine signal kinases activated by ERK1/2 [60]. 0.31 
 
0.005 
 
pGSK3 α(pS21), 
β(pS9) 
Serine/threonine kinase that phosphorylates and inactivates glycogen 
synthase kinase (GSK); dysregulation of GSK3 associated with cancer 
[61]. 
 
0.31 
 
 
 
0.006 
β-Catenin Key component of Wnt signalling pathway, and regulator of cell-cell 
adhesion and epithelial-mesenchymal transition [62].  
 
0.27 
 
 
0.017 
AKT (pS473) Serine/threonine kinase involved in regulation of metabolism, cell 
survival, and growth; pAKT detected at high frequency in breast cancer 
[63]. 
 
0.26 
 
 
 
0.020 
NF2 Encodes tumour suppressor protein Merlin (Moesin-ezrin-radixin-like-
protein); NF2 mutations may be linked with breast cancer [64]. 
0.24 
 
 
0.031 
Src (pY416) Tyrosine kinase involved in regulation of cell growth and differentiation, 
and cancer cell epithelial-mesenchymal transition. Phosphorylation at 
Y416 is indicative of the active enzyme [65].  
 
0.23 
 
 
 
0.038 
 
Notch1 
 
Receptor for Jagged1/2 and delta-like proteins 1/3/4 [66]. Higher Notch1 
activity in basal breast cancer; overexpression of Notch1 correlates with 
poor patient survival [67]. 
 
-0.22 
 
 
 
 
0.051 
FOXO3a Transcription factor involved in cell death, cell cycle arrest and DNA 
damage repair. Inactivation of FOXO proteins is linked to breast cancer 
tumourigenesis [68]. 
 
-0.23 
 
 
 
0.044 
ACC1 Acetyl-CoA carboxylase; involved in lipogenic pathways and up-
regulated in breast cancer [69]. 
 
-0.23 
 
 
0.044 
p27 (pT157) Ubiquitously expressed kinase inhibitor protein involved in cell cycle 
regulation [70]. 
 
-0.24 
 
 
0.032 
Chk1 Serine/threonine kinase involved in G2/M cell cycle arrest and DNA 
damage repair [71]. 
 
-0.25 
 
 
0.028 
Smad4 Involved in TGF β signalling which plays a role in breast cancer 
carcinogenesis [72]. 
 
-0.25 
 
 
0.025 
Cyclin B1 Regulatory subunit of cyclin-dependent kinase 1 (CDK1); important for 
entry into mitosis [73]. 
 
-0.26 
 
 
0.020 
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